Tenax Therapeutics Inc.

NASDAQ: TENX · Real-Time Price · USD
5.85
-0.10 (-1.68%)
At close: Aug 15, 2025, 12:51 PM

Tenax Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a 7.57K 113.33K 108.98K
Gross Profit
n/a -7.57K -113.33K -108.98K
Operating Income
-19.49M -8.23M -11.05M -32.73M
Interest Income
1.91M n/a 4.44 n/a
Pretax Income
-17.6M -7.71M -11.05M -32.47M
Net Income
-17.6M -7.71M -11.05M -32.47M
Selling & General & Admin
6.79M 5.01M 5.68M 7.58M
Research & Development
12.71M 3.23M 5.38M 25.15M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
19.49M 8.23M 11.05M 32.73M
Interest Expense
23K 23.97K 4.44K 949.00
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
-19.49M 8.23M 11.05M 32.73M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
15.27M 248K 18.39K 12.86K
Shares Outstanding (Diluted)
15.27M 248.45K 18.39K 12.86K
EPS (Basic)
-1.15 -31.09 -600.8 -2.52K
EPS (Diluted)
-1.15 -31.04 -600.8 -2.52K
EBITDA
-17.58M -7.68M -10.93M -32.36M
EBIT
-17.63M -7.69M -11.04M -32.47M
Depreciation & Amortization
46K 7.57K 113.33K 108.98K